Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 Akedo Akedo +48.65%
#3 DOVU DOVU +48.14%
#4 Velvet Velvet +43.34%
#5 Black Phoenix Black Phoenix +33.95%
#6 Cross Cross +24.30%
#7 Cap Cap +20.40%
#8 DoubleZero DoubleZero +15.97%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.98%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +9.29%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Classement en actions #33956
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Prix de l'action
$17.15
Dernière synchronisation: 2026-08-03
Capitalisation boursière
$6.51M
Changement (1 jour)
9.80%
Changement (1 an)
289.77%
Pays
US
Échange Galera Therapeutics, Inc. (GRTX)

Catégorie

Healthcare
Revenus pour Galera Therapeutics, Inc. (GRTX)
Revenus en Mar 2026 TTM : 0.00
Selon les derniers rapports financiers de Galera Therapeutics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0.00. En 2023, l'entreprise a réalisé un chiffre d'affaires de 0.00 égal à le chiffre d'affaires de l'année 2022, qui était de 0.00. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Galera Therapeutics, Inc. de 2017 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE